Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study

医学 内科学 四分位间距 危险系数 化疗 食管切除术 新辅助治疗 卡铂 胃肠病学 养生 食管癌 肿瘤科 临床研究阶段 外科 置信区间 癌症 乳腺癌 顺铂
作者
Yang Yang,Jun Liu,Zhichao Liu,Li Zhu,Hezhong Chen,Bentong Yu,Renquan Zhang,Jinchen Shao,Ming Zhang,Chun Guang Li,Zhigang Li
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [Elsevier BV]
卷期号:167 (3): 838-847.e1 被引量:51
标识
DOI:10.1016/j.jtcvs.2023.08.056
摘要

Objective This study aims to report the 2-year outcomes of patients with clinical stage N2-3 esophageal squamous cell carcinoma who received neoadjuvant chemotherapy and immunotherapy followed by surgery from a phase 2 NICE trial. Methods Eligible patients with clinical stage N2-3 esophageal squamous cell carcinoma were screened and enrolled, then treated with regimen of nab-paclitaxel (100 mg/m2, days 1, 8, 15), carboplatin (area under the curve = 5, day 1), camrelizumab (200 mg, day 1) of two 21-day cycles and esophagectomy 4 to 6 weeks after the last chemotherapy. Oncologic outcomes, recurrence patterns, overall survival (OS), and recurrence-free survival (RFS) were explored. Results From November 20, 2019, to December 22, 2020, 60 patients were recruited. After a median follow-up of 27.4 months, disease recurrence was observed in 19 (37.3%) patients, with 5 (9.8%) locoregional recurrence, 9 (17.6%) distant metastasis, and 5 (9.8%) combined recurrence. Lung was the most commonly involved metastatic site. The median time to recurrence was 10.8 months (interquartile range, 7.5-12.7 months). The 2-year OS and RFS rates were 78.1% and 67.9%, respectively. Patients who achieved major pathologic response (MPR) had a significantly greater 2-year OS rate (91.4% vs 47.7%; P < .001) and RFS rate (77.1% vs 45.9%; P = .003). On multivariable analysis, MPR was indicated as an independent prognostic factor for disease recurrence (hazard ratio, 0.39; 95% confidence interval, 0.21-0.82; P = .029). Conclusions In patients receiving neoadjuvant chemotherapy and immunotherapy, distant metastasis remains the predominant recurrence pattern. MPR is associated with lower recurrence and better survival. Long-term results derived from randomized controlled trials are further required. Trial registration number ChiCTR1900026240.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Code_king发布了新的文献求助10
刚刚
Code_king发布了新的文献求助10
1秒前
1秒前
JamesPei的应助被Pepsi采纳,获得30
1秒前
1秒前
KFjiatang完成签到,获得积分20
1秒前
1秒前
1秒前
Qxk完成签到,获得积分10
2秒前
橙啊程完成签到 ,获得积分10
2秒前
2秒前
Ray完成签到,获得积分10
2秒前
2秒前
Code_king发布了新的文献求助10
2秒前
体贴怜翠发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
3秒前
顾矜的应助被Mnjr采纳,获得10
3秒前
罗林发布了新的文献求助10
4秒前
Code_king发布了新的文献求助10
4秒前
科目三的应助被100毫升采纳,获得10
5秒前
shanlu完成签到,获得积分10
5秒前
5秒前
5秒前
zw关注了科研通微信公众号
5秒前
共享精神的应助被庸人自扰采纳,获得10
5秒前
农夫完成签到,获得积分10
5秒前
Code_king发布了新的文献求助10
5秒前
Qxk发布了新的文献求助10
6秒前
6秒前
啦啦啦完成签到,获得积分10
6秒前
Code_king发布了新的文献求助10
6秒前
Code_king发布了新的文献求助10
6秒前
Huangzhisong发布了新的文献求助30
6秒前
Code_king发布了新的文献求助10
6秒前
lvy发布了新的文献求助10
6秒前
BTW关闭了BTW的文献求助
6秒前
吴华鑫发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177135
求助须知:如何正确求助?哪些是违规求助? 9568196
关于积分的说明 21797695
捐赠科研通 7771894
什么是DOI,文献DOI怎么找? 3432251
关于科研通互助平台的介绍 2556506
邀请新用户注册赠送积分活动 2477791